Search Within

Parisa Momtaz

Refine Results
Formats
  1. Journal Article (9)
  2. Book Section (4)
  3. Meeting Abstract (2)
Groups
  1. Melanoma and Immunotherapeutics Service (15)
  2. Solid Tumor Oncology Division (15)
  3. Melanoma Disease Management Team (12)
  4. Central Nervous System Disease Management Team (9)
  5. Population Sciences Research Program (9)
  6. Biostatistics Service (7)

More Groups

People
  1. Paul Chapman (10)
  2. Michael Postow (9)
  3. Jedd Wolchok (8)
  4. Katherine Panageas (7)
  5. Margaret Callahan (7)
  6. Alexander Shoushtari (5)

More People

Years
  1. 2018 (1)
  2. 2017 (2)
  3. 2016 (3)
  4. 2015 (3)
  5. 2014 (6)
Publications
  1. Journal of Clinical Oncology (5)
  2. Pocket Oncology (4)
  3. Oncotarget (2)
  4. JAMA Oncology (1)
  5. JNCI: Journal of the National Cancer Institute (1)
  6. Pharmacogenomics and Personalized Medicine (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Wolters Kluwer Health | Lippincott Williams & Wilkins (4)
  3. Impact Journals (2)
  4. AlphaMed Press (1)
  5. American Medical Association (1)
  6. Dove Medical Press Ltd (1)

More Publishers

Results (15)

Export to EndNote | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma
    Journal Article

    Shoushtari, A. N.; Friedman, C. F.; Navid-Azarbaijani, P.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Panageas, K. S.; Wolchok, J. D.; Chapman, P. B.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
    Journal Article

    Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab + ipilimumab
    Journal Article

    Friedman, C. F.; Clark, V.; Raikhel, A. V.; Barz, T.; Shoushtari, A. N.; Momtaz, P.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; Hellmann, M. D.; more...
    JNCI: Journal of the National Cancer Institute (2017)

    Fulltext@MSK | Save
  • Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies
    Journal Article

    Momtaz, P.; Pentsova, E.; Abdel-Wahab, O.; Diamond, E.; Hyman, D.; Merghoub, T.; You, D.; Gasmi, B.; Viale, A.; Chapman, P. B.
    Oncotarget (2016)

    Fulltext@MSK | Save
  • Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis
    Journal Article

    Kuk, D.; Shoushtari, A. N.; Barker, C. A.; Panageas, K. S.; Munhoz, R. R.; Momtaz, P.; Ariyan, C. E.; Brady, M. S.; Coit, D. G.; Bogatch, K.; more...
    The Oncologist (2016)

    Fulltext@MSK | Save
  • Reply to A. Indini et al.
    Journal Article

    Horvat, T. Z.; Adel, N. G.; Dang, T. O.; Momtaz, P.; Postow, M. A.; Callahan, M. K.; Carvajal, R. D.; Dickson, M. A.; D'Angelo, S. P.; Woo, K. M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab over 30 minutes
    Journal Article

    Momtaz, P.; Park, V.; Panageas, K. S.; Postow, M. A.; Callahan, M.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center
    Journal Article

    Horvat, T. Z.; Adel, N. G.; Dang, T. O.; Momtaz, P.; Postow, M. A.; Callahan, M. K.; Carvajal, R. D.; Dickson, M. A.; D'Angelo, S. P.; Woo, K. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab (ipi) over 30 minutes (min)
    Meeting Abstract

    Momtaz, P.; Park, V.; Panageas, K.; Guillen, J. D.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR (DigPCR) with tumor burden measured radiographically in patients (pts) with BRAF(V600E)mutated melanoma (mel) treated with RAF inhibitor (RAFi) and/or ipilimumab (Ipi)
    Meeting Abstract

    Momtaz, P.; Gaskell, A. A.; Merghoub, T.; Viale, A.; Chapman, P. B.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save